Home  >  TopNews
Corporate
+ Font Resize -

Indian pharma market clocks growth of 2.8% to Rs.10,420 crore in September 2017

Our Bureau, Mumbai
Thursday, October 12, 2017, 08:00 Hrs  [IST]

Indian Pharmaceutical Market (IPM) has registered a growth of only 2.8 per cent during September 2017 to Rs.10, 420 crore and 3.7 per cent during the first half ended April-September 2017. According to AIOCD Pharmasofttech AWACS Pvt Ltd report, the half yearly growth has been affected due to GST run up and implementation. The volumes of established product have shown a turnaround in this month. However, price component will continue to pull the market down.

Anti-infectives are showing degrowth for the month and declined by 2.4 per cent, while dermatology is still posting a double digit positive growth of 12 per cent. However, gastrointestinal is growing at 2.4 per cent while vitamins have posted a slight negative growth of 0.8 per cent. Major chronic therapy like anti-diabetic has shown a double digit growth of 10.7 per cent. Cardio segment has posted single digit growth for the month of 5.9 per cent which is slower than the August 2017 growth, CNS has slumped to 1.8 per cent. Only derma and anti-diabetics segments are showing double digit growth in first half to 10.8 per cent and 14.1 per cent respectively on half yearly basis amongst the top 10 segments.

For the month of September 2017, GDs improved to 9.1 per cent in volumes. FDC related market shows a small growth of 1.4 per cent while the non FDC market showed a growth of 3.3 per cent, while the single molecules grew at 2.4 per cent for the month of September 2017. Price component is pulling down the growth for the FDCs. The GDs in terms of volumes at 5 per cent while prices are declining 4 per cent and new products are growing at 0.4 per cent. The non FDC component growth drivers are volumes at 9.1 per cent, while new products are growing at 2.8 per cent. The single molecules are driven by volumes at 9.3 per cent, however, the prices are pulling down at by 9.8 per cent while NPs are growing at 2.9 per cent. MNC are growing at 3.9 per cent which is faster than the Indian companies which are growing at 2.5 per cent.

Amongst the top 10 corporates, Mankind has the highest growth at 11.8 per cent followed by GSK at 8.4 per cent and Abbott at 6.1 per cent. Glaxo has posted a good positive growth of 8.4 per cent for Sept 2017. GSK recovering month after month. Among the top 50 corporates, 33 corporates registered positive growth of IPM for the month. Natco Pharma has the highest growth of 20.5 per cent followed by Hetero growing at 17.9 per cent and Himalaya growing at 13.1 per cent.

Amongst the 51-60 ranked corporates, Eli Lilly leads at 21 per cent followed by Corona at 18.3 per cent and Allergan growing at 17.9 per cent. Abbott HC is growing at 5.1 per cent while Abbott India is growing at 9.8 per cent. Sun portfolio has shown a small growth at 1.5 per cent, while Ranbaxy has registered 3.3 per cent growth. Total 30 companies launched in last 36 months and out of these 2 companies cross Rs.10 crore in revenue.

Indian companies showed a slower growth at 2.5 per cent for the month while the MNCs grown faster than the Indian companies at 3.9 per cent. Amongst the top 60 MNCs, Eli Lilly was the fastest growing at 21 per cent followed by Allergan which grew at 17.9 per cent and Sanofi which is growing at 11.2 per cent for Sept 2017. In the non-NLEM category Indian companies showed a growth of 3.2 per cent whereas MNCs grew at 4.2 per cent.

The NLEM 2013 containing molecules market degrew at 1.7 per cent whereas the non-NLEM market grew at 3.4 per cent resulting in an overall growth of 2.9 per cent for the month of September 2017.

From therapy perspective 15 therapies are showing a positive growth for the month of September. Respiratory market posted a growth of 2.3 per cent, gastrointestinal market showed growth of 2.4 per cent, while pain and analgesic decline at 0.9 per cent. Anti-diabetic market grew at 10.7 per cent & Cardiac at 5.9 per cent, Neuro/CNS is stagnant at 1.8 per cent growth for the month of Sept 2017 amongst the chronic care categories. Anti-malarials degrew at 25.8 per cent & VMS market declined at 0.3 per cent. Derma is growing at 12 per cent for September 2017 which is faster than the monthly growth rate of anti-diabetics segment.

From regional perspective 21 regions have posted positive growth for the month of Sept 2017. North Karnataka market grew the highest at 18 per cent followed by outer Mumbai at 17.7 per cent and Mumbai city at 16.7 per cent.

Amoxycillin + clavulanic acid market was stagnant at 0.74 per cent growth in September 2017. Glimepiride + metformin market was also stagnant at 1.55 per cent growth. Glimepiride + metformin was pegged at Rs.168 crore & amoxycillin + clavulanic acid market at Rs.179.8 crore in September 2017. Azilsartan market is now valued at Rs.39.3 crore on Mat basis. Sofosbuvir and its combination market has reached at Rs.570.4 crore on Mat basis. The luliconazole market is worth at Rs.183 crore on MAT basis. While tenegliptin and its combinations are pegged at Rs.534.9 crore. The market of paracetamol plain showed a de-growth of 5.4 per cent on monthly basis, plain atorvastatin is declining at 5.44 per cent.

Among the major brands, Mixtard leads the pack with Rs.41.1 crore followed by Glycomet GP at Rs.35.1 crore, Spasmoproxyvon Plus at Rs.36.8 crore, Lantus at Rs.31.1 crore & Galvus Met at Rs.32.9 crore and Liv 52 at Rs.30.7 crore and Janumet at Rs.31.1 crore. Few brands who have gained ranks on MAT basis include Novomix (+10), Combiflam (+3), Cilacar (+27), Udiliv (+22), Ultracet (+12), Duolin, (+31), Gluconorm G (+17), Telma H (+11), Allegra (+19), Synflorix (+13), Gemer (+11), Ecosprin AV (+21), Duphaston (+16), Jalra M(+5).

Azilsartan is a recently launched molecule now valued at Rs.39.3 crore there are 38 brands already launched. On MAT basis with Zilarbi (Emcure) leading followed by Aztric (Intas) and Abel (Lupin). Luliconazole segment is worth at Rs.183 crore on MAT basis there are already 34 brands in the foray. Benidipine molecule and its combinations is now valued at Rs.11 crore on MAT basis with Inzit (Eris) leading followed by Benitowa (Akumentis) and Benipack (Koye).

Within the Anti-diabetic category there are 3 brands launched in the month of Sept 2017 and that in VMS category there have been 7 brands launched. Within cardiac there have been 10 brands launched in Sept '17, Bengreat, Amifru Plus, Ibitan are the top three brands launched in September 2017.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
pradeep Awasthi Oct 12, 2017 9:31 AM
The September month outlook of Indian pharma market shows poor growth of 2.8% and 3.7% growth on half yearly basis from April-sept17. The main factor which had pull down the market growth of first six months is pre and post effect of new taxation regime GST.

The indepth analysis suggest that no segment except dermatology and antidiabetic which is able to sustain growth of more than double digit.equally so far as highest growth contributor companies are concern only mankind and GSK have surpassed more than 10% growth and Abbot with 6% on monthly basis,Moreover only two regions had posted growth in double digits for month are Karnataka and Mumbai.



 
IPJPI_150x60en_2017
acssymposium
CPhI-WWW-150x60-stat-v1
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |